JP2012515225A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012515225A5 JP2012515225A5 JP2011546409A JP2011546409A JP2012515225A5 JP 2012515225 A5 JP2012515225 A5 JP 2012515225A5 JP 2011546409 A JP2011546409 A JP 2011546409A JP 2011546409 A JP2011546409 A JP 2011546409A JP 2012515225 A5 JP2012515225 A5 JP 2012515225A5
- Authority
- JP
- Japan
- Prior art keywords
- benzo
- optionally substituted
- pyridazin
- triazole
- dihydro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14544809P | 2009-01-16 | 2009-01-16 | |
| US61/145,448 | 2009-01-16 | ||
| PCT/US2010/021275 WO2010083465A1 (en) | 2009-01-16 | 2010-01-15 | Axl inhibitors for use in combination therapy for preventing, treating or managing metastatic cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014208912A Division JP2015007135A (ja) | 2009-01-16 | 2014-10-10 | 転移性癌の予防、治療、または管理のための併用療法に用いるためのａｘｌ阻害薬 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012515225A JP2012515225A (ja) | 2012-07-05 |
| JP2012515225A5 true JP2012515225A5 (https=) | 2013-02-28 |
| JP5858789B2 JP5858789B2 (ja) | 2016-02-10 |
Family
ID=41683427
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011546409A Active JP5858789B2 (ja) | 2009-01-16 | 2010-01-15 | 転移性癌の予防、治療、または管理のための併用療法に用いるためのａｘｌ阻害薬 |
| JP2014208912A Pending JP2015007135A (ja) | 2009-01-16 | 2014-10-10 | 転移性癌の予防、治療、または管理のための併用療法に用いるためのａｘｌ阻害薬 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014208912A Pending JP2015007135A (ja) | 2009-01-16 | 2014-10-10 | 転移性癌の予防、治療、または管理のための併用療法に用いるためのａｘｌ阻害薬 |
Country Status (13)
| Country | Link |
|---|---|
| US (5) | US8546433B2 (https=) |
| EP (1) | EP2387395B1 (https=) |
| JP (2) | JP5858789B2 (https=) |
| CN (1) | CN102281875B (https=) |
| AU (1) | AU2010204578B2 (https=) |
| BR (1) | BRPI1007046B1 (https=) |
| CA (1) | CA2749843C (https=) |
| ES (1) | ES2528032T3 (https=) |
| PL (1) | PL2387395T3 (https=) |
| PT (1) | PT2387395E (https=) |
| RU (1) | RU2555326C2 (https=) |
| SG (1) | SG172997A1 (https=) |
| WO (1) | WO2010083465A1 (https=) |
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007030680A2 (en) * | 2005-09-07 | 2007-03-15 | Rigel Pharmaceuticals, Inc. | Triazole derivatives useful as axl inhibitors |
| ES2672172T3 (es) * | 2006-12-29 | 2018-06-12 | Rigel Pharmaceuticals, Inc. | Triazoles N3-heteroarilsustituidos y triazoles N5-heteroarilsustituidos útiles como inhibidores de Axl |
| WO2008083353A1 (en) | 2006-12-29 | 2008-07-10 | Rigel Pharmaceuticals, Inc. | Bicyclic aryl and bicyclic heteroaryl substituted triazoles useful as axl inhibitors |
| EP2079736B1 (en) | 2006-12-29 | 2017-10-18 | Rigel Pharmaceuticals, Inc. | Substituted triazoles useful as axl inhibitors |
| EP2114955B1 (en) | 2006-12-29 | 2013-02-13 | Rigel Pharmaceuticals, Inc. | Bridged bicyclic aryl and bridged bicyclic heteroaryl substituted triazoles useful as axl inhibitors |
| EP2078010B1 (en) | 2006-12-29 | 2014-01-29 | Rigel Pharmaceuticals, Inc. | Polycyclic heteroaryl substituted triazoles useful as axl inhibitors |
| WO2009054864A1 (en) * | 2007-10-26 | 2009-04-30 | Rigel Pharmaceuticals, Inc. | Polycyclic aryl substituted triazoles and polycyclic heteroaryl substituted triazoles useful as axl inhibitors |
| US8309566B2 (en) | 2008-02-15 | 2012-11-13 | Rigel Pharmaceuticals, Inc. | Pyrimidine-2-amine compounds and their use as inhibitors of JAK kinases |
| US8431594B2 (en) | 2008-07-09 | 2013-04-30 | Rigel Pharmaceuticals, Inc. | Bridged bicyclic heteroaryl substituted triazoles useful as AXL inhibitors |
| CA2730231C (en) | 2008-07-09 | 2016-10-18 | Rigel Pharmaceuticals, Inc. | Polycyclic heteroaryl substituted triazoles useful as axl inhibitors |
| JP4644273B2 (ja) * | 2008-07-15 | 2011-03-02 | 本田技研工業株式会社 | 車両周辺監視装置 |
| SG172997A1 (en) | 2009-01-16 | 2011-08-29 | Rigel Pharmaceuticals Inc | Axl inhibitors for use in combination therapy for preventing, treating or managing metastatic cancer |
| US8916574B2 (en) | 2009-09-28 | 2014-12-23 | Qilu Pharmaceutical Co., Ltd. | 4-(substituted anilino)-quinazoline derivatives useful as tyrosine kinase inhibitors |
| GB201207722D0 (en) | 2012-05-02 | 2012-06-13 | Bergenbio As | Method |
| CA2879542A1 (en) | 2012-07-25 | 2014-01-30 | Salk Institute For Biological Studies | Regulating the interaction between tam ligands and lipid membranes with exposed phosphatidylserine |
| JP6527513B2 (ja) | 2013-11-20 | 2019-06-05 | シグナルケム・ライフサイエンシーズ・コーポレイションＳｉｇｎａｌｃｈｅｍ Ｌｉｆｅｓｃｉｅｎｃｅｓ Ｃｏｒｐｏｒａｔｉｏｎ | Ｔａｍファミリーキナーゼ阻害剤としてのキナゾリン誘導体 |
| JP6496731B2 (ja) | 2013-11-27 | 2019-04-03 | シグナルケム・ライフサイエンシーズ・コーポレイションＳｉｇｎａｌｃｈｅｍ Ｌｉｆｅｓｃｉｅｎｃｅｓ Ｃｏｒｐｏｒａｔｉｏｎ | Ｔａｍファミリーキナーゼ阻害剤としてのアミノピリジン誘導体 |
| JP6992960B2 (ja) * | 2013-12-02 | 2022-02-03 | ベルゲンビオ アーエスアー | キナーゼ阻害剤の用途 |
| US20170027940A1 (en) * | 2014-04-10 | 2017-02-02 | Stichting Het Nederlands Kanker Instituut | Method for treating cancer |
| US10028958B2 (en) * | 2014-04-19 | 2018-07-24 | Massachusetts Institute Of Technology | Methods of treating cancer with a combination of selected MEK1/2 and AXL inhibitors |
| GB201420285D0 (en) | 2014-11-14 | 2014-12-31 | Bergenbio As | Process |
| GB201509338D0 (en) * | 2015-05-29 | 2015-07-15 | Bergenbio As | Combination therapy |
| CN106083764B (zh) * | 2016-07-11 | 2018-09-18 | 上海皓元生物医药科技有限公司 | 一种用于制备axl抑制剂的高纯度中间体的手性拆分方法 |
| CN109384774B (zh) * | 2017-08-11 | 2023-02-17 | 中国科学院上海药物研究所 | 一类多取代的吡嗪/三嗪酰胺类化合物及其制备方法和应用 |
| US20200289613A1 (en) * | 2017-11-04 | 2020-09-17 | Aravive Biologics, Inc. | Methods of treating metastatic cancers using axl decoy receptors |
| US12097194B2 (en) | 2018-09-18 | 2024-09-24 | Signalchem Lifesciences Corporation | Combination therapy for treating blood cancer |
| US20220143049A1 (en) | 2019-03-21 | 2022-05-12 | Onxeo | A dbait molecule in combination with kinase inhibitor for the treatment of cancer |
| GB201912059D0 (en) | 2019-08-22 | 2019-10-09 | Bergenbio As | Combaination therapy of a patient subgroup |
| EP4054579A1 (en) | 2019-11-08 | 2022-09-14 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
| WO2021138391A1 (en) | 2019-12-30 | 2021-07-08 | Tyra Biosciences, Inc. | Indazole compounds |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| GB202004189D0 (en) | 2020-03-23 | 2020-05-06 | Bergenbio As | Combination therapy |
| GB202006072D0 (en) | 2020-04-24 | 2020-06-10 | Bergenbio Asa | Method of selecting patients for treatment with cmbination therapy |
| GB202104037D0 (en) | 2021-03-23 | 2021-05-05 | Bergenbio Asa | Combination therapy |
| JPWO2022220227A1 (https=) * | 2021-04-14 | 2022-10-20 | ||
| GB202209285D0 (en) | 2022-06-24 | 2022-08-10 | Bergenbio Asa | Dosage regimen for AXL inhibitor |
| AR129722A1 (es) | 2022-06-28 | 2024-09-18 | Arcus Biosciences Inc | Compuestos inhibidores de axl |
| EP4687905A1 (en) | 2023-03-30 | 2026-02-11 | Revolution Medicines, Inc. | Compositions for inducing ras gtp hydrolysis and uses thereof |
| AU2024265078A1 (en) | 2023-05-04 | 2025-12-11 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| IL326136A (en) | 2023-08-07 | 2026-03-01 | Revolution Medicines Inc | RMC-6291 for use in the treatment of a disease or disorder associated with the RAS protein |
| US20250154171A1 (en) | 2023-10-12 | 2025-05-15 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1403866A (en) * | 1971-12-06 | 1975-08-28 | Wyeth John & Brother Ltd | Derivatives of 3-amino-1,2,4-triazoles |
| US4512992A (en) * | 1980-06-13 | 1985-04-23 | Burroughs Wellcome Co. | Treatment with dialkoxy pyridopyrimidine compounds |
| MX19185A (es) | 1989-01-20 | 1993-12-01 | Pfizer | Procedimiento para preparar 3-(1,2,5,6-tretrahidropiridil)-pirrolopiridinas. |
| US6258360B1 (en) | 1989-05-04 | 2001-07-10 | Igen International, Inc. | Prodrugs activated by targeted catalytic proteins |
| WO1995003286A1 (en) | 1993-07-23 | 1995-02-02 | The Green Cross Corporation | Triazole derivative and pharmaceutical use thereof |
| UA71971C2 (en) * | 1999-06-04 | 2005-01-17 | Agoron Pharmaceuticals Inc | Diaminothiazoles, composition based thereon, a method for modulation of protein kinases activity, a method for the treatment of diseases mediated by protein kinases |
| GB9918180D0 (en) | 1999-08-02 | 1999-10-06 | Smithkline Beecham Plc | Novel compositions |
| DE60120494T2 (de) | 2000-12-22 | 2006-12-21 | Ortho-Mcneil Pharmaceutical, Inc. | Substituieten triazoldiamin derivaten und ihre verwendung als kinase inhibitoren |
| DE10123586A1 (de) * | 2001-05-08 | 2002-11-28 | Schering Ag | 3,5-Diamino-1,2,4-triazole als Kinase Inhibitoren |
| TW201041580A (en) | 2001-09-27 | 2010-12-01 | Alcon Inc | Inhibitors of glycogen synthase kinase-3 (GSK-3) for treating glaucoma |
| AU2003217961B2 (en) | 2002-03-08 | 2008-02-28 | Signal Pharmaceuticals, Llc | Combination therapy for treating, preventing or managing proliferative disorders and cancers |
| CN1290893C (zh) | 2002-05-03 | 2006-12-20 | 詹森药业有限公司 | 聚合物微乳状液 |
| US20060293256A1 (en) * | 2002-08-06 | 2006-12-28 | Masateru Yamada | Remedy or preventive for kidney disease and method of diagnosing kidney disease |
| AU2003286746A1 (en) | 2002-10-29 | 2004-05-25 | Rigel Pharmaceuticals, Inc. | Modulators of angiogenesis and tumorigenesis |
| CL2003002353A1 (es) * | 2002-11-15 | 2005-02-04 | Vertex Pharma | Compuestos derivados de diaminotriazoles, inhibidores d ela proteina quinasa; composicion farmaceutica; procedimiento de preparacion; y su uso del compuesto en el tratamiento de enfermedades de desordenes alergicos, proliferacion, autoinmunes, condic |
| AU2004220176A1 (en) | 2003-03-14 | 2004-09-23 | Astrazeneca Ab | Novel fused triazolones and the uses thereof |
| MXPA05013434A (es) | 2003-06-12 | 2006-03-17 | Astellas Pharma Inc | Derivados de benzamida o sal del mismo. |
| WO2005013982A1 (en) | 2003-08-06 | 2005-02-17 | Vertex Pharmaceuticals Incorporated | Aminotriazole compounds useful as inhibitors of protein kinases |
| CA2554925A1 (en) | 2004-01-30 | 2005-08-11 | Ab Science | 2-(3-substituted-aryl)amino-4-aryl-thiazoles as tyrosine kinase inhibitors |
| EP1720843A2 (en) | 2004-02-11 | 2006-11-15 | Janssen Pharmaceutica N.V. | Process for the preparation of substituted triazole compounds |
| EP1763514A2 (en) | 2004-05-18 | 2007-03-21 | Rigel Pharmaceuticals, Inc. | Cycloalkyl substituted pyrimidinediamine compounds and their uses |
| SG155222A1 (en) | 2004-08-13 | 2009-09-30 | Genentech Inc | Thiazole based inhibitors of atp-utilizing enzymes |
| KR20070057955A (ko) | 2004-09-17 | 2007-06-07 | 버텍스 파마슈티칼스 인코포레이티드 | 단백질 키나제 억제제로서 유용한 디아미노트리아졸 화합물 |
| SI1811998T1 (sl) | 2004-10-21 | 2011-01-31 | Vertex Pharma | Triazoli uporabni kot inhibitorji proteinskih kinaz |
| US20060166936A1 (en) | 2004-10-29 | 2006-07-27 | Hayley Binch | Diaminotriazole compounds useful as inhibitors of protein kinases |
| RU2007123675A (ru) | 2004-11-24 | 2008-12-27 | Новартис АГ (CH) | Комбинации ингибиторов jak |
| US20070166388A1 (en) * | 2005-02-18 | 2007-07-19 | Desai Neil P | Combinations and modes of administration of therapeutic agents and combination therapy |
| WO2007030680A2 (en) | 2005-09-07 | 2007-03-15 | Rigel Pharmaceuticals, Inc. | Triazole derivatives useful as axl inhibitors |
| JP5400388B2 (ja) | 2005-12-15 | 2014-01-29 | ライジェル ファーマシューティカルズ， インコーポレイテッド | キナーゼインヒビターおよびその利用 |
| WO2007118149A2 (en) | 2006-04-07 | 2007-10-18 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical Lollege | Thiazole and thiophene analogues, and their use in treating autoimmune diseases and cancers |
| WO2008045978A1 (en) | 2006-10-10 | 2008-04-17 | Rigel Pharmaceuticals, Inc. | Pinane-substituted pyrimidinediamine derivatives useful as axl inhibitors |
| FR2908131B1 (fr) | 2006-11-03 | 2009-01-09 | Univ Haute Alsace Etablissemen | Derives d'aminobenzocycloheptene,leurs procedes de preparation et leur utilisation en therapeutique |
| JP2008130120A (ja) | 2006-11-17 | 2008-06-05 | Sharp Corp | 光ピックアップ装置 |
| WO2008080134A2 (en) | 2006-12-22 | 2008-07-03 | Rigel Pharmaceuticals, Inc. | 4-amin0-2- (hetero) arylamino-5- (hetero) arylthiazoles useful as axl inhibitors |
| ES2672172T3 (es) | 2006-12-29 | 2018-06-12 | Rigel Pharmaceuticals, Inc. | Triazoles N3-heteroarilsustituidos y triazoles N5-heteroarilsustituidos útiles como inhibidores de Axl |
| EP2114955B1 (en) | 2006-12-29 | 2013-02-13 | Rigel Pharmaceuticals, Inc. | Bridged bicyclic aryl and bridged bicyclic heteroaryl substituted triazoles useful as axl inhibitors |
| EP2078010B1 (en) | 2006-12-29 | 2014-01-29 | Rigel Pharmaceuticals, Inc. | Polycyclic heteroaryl substituted triazoles useful as axl inhibitors |
| EP2079736B1 (en) * | 2006-12-29 | 2017-10-18 | Rigel Pharmaceuticals, Inc. | Substituted triazoles useful as axl inhibitors |
| WO2008083353A1 (en) | 2006-12-29 | 2008-07-10 | Rigel Pharmaceuticals, Inc. | Bicyclic aryl and bicyclic heteroaryl substituted triazoles useful as axl inhibitors |
| AU2008266290A1 (en) | 2007-06-15 | 2008-12-24 | Irm Llc | Protein kinase inhibitors and methods for using thereof |
| WO2009054864A1 (en) | 2007-10-26 | 2009-04-30 | Rigel Pharmaceuticals, Inc. | Polycyclic aryl substituted triazoles and polycyclic heteroaryl substituted triazoles useful as axl inhibitors |
| US8309566B2 (en) * | 2008-02-15 | 2012-11-13 | Rigel Pharmaceuticals, Inc. | Pyrimidine-2-amine compounds and their use as inhibitors of JAK kinases |
| CA2730231C (en) | 2008-07-09 | 2016-10-18 | Rigel Pharmaceuticals, Inc. | Polycyclic heteroaryl substituted triazoles useful as axl inhibitors |
| US8431594B2 (en) | 2008-07-09 | 2013-04-30 | Rigel Pharmaceuticals, Inc. | Bridged bicyclic heteroaryl substituted triazoles useful as AXL inhibitors |
| SG172997A1 (en) * | 2009-01-16 | 2011-08-29 | Rigel Pharmaceuticals Inc | Axl inhibitors for use in combination therapy for preventing, treating or managing metastatic cancer |
-
2010
- 2010-01-15 SG SG2011051174A patent/SG172997A1/en unknown
- 2010-01-15 EP EP10700686.8A patent/EP2387395B1/en active Active
- 2010-01-15 ES ES10700686.8T patent/ES2528032T3/es active Active
- 2010-01-15 RU RU2011132118/15A patent/RU2555326C2/ru active
- 2010-01-15 BR BRPI1007046-0A patent/BRPI1007046B1/pt active IP Right Grant
- 2010-01-15 CN CN201080004818.0A patent/CN102281875B/zh active Active
- 2010-01-15 WO PCT/US2010/021275 patent/WO2010083465A1/en not_active Ceased
- 2010-01-15 US US12/688,746 patent/US8546433B2/en active Active
- 2010-01-15 PL PL10700686T patent/PL2387395T3/pl unknown
- 2010-01-15 CA CA2749843A patent/CA2749843C/en active Active
- 2010-01-15 PT PT107006868T patent/PT2387395E/pt unknown
- 2010-01-15 JP JP2011546409A patent/JP5858789B2/ja active Active
- 2010-01-15 AU AU2010204578A patent/AU2010204578B2/en active Active
-
2013
- 2013-06-03 US US13/908,874 patent/US20130338161A1/en not_active Abandoned
-
2014
- 2014-10-10 JP JP2014208912A patent/JP2015007135A/ja active Pending
-
2016
- 2016-03-22 US US15/077,648 patent/US20170042891A1/en not_active Abandoned
-
2019
- 2019-03-12 US US16/351,130 patent/US20190336500A1/en not_active Abandoned
-
2021
- 2021-06-18 US US17/351,996 patent/US20210379064A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012515225A5 (https=) | ||
| RU2011132118A (ru) | Ингибиторы axl для применения в комбинированной терапии для предотвращения, устранения или лечения метастизирующего рака | |
| JP7846091B2 (ja) | 複素環式化合物およびその使用 | |
| JP2020105211A5 (https=) | ||
| US11952386B2 (en) | N-azaspirocycloalkane substituted N-heteroaryl compounds and compositions for inhibiting the activity of SHP2 | |
| JP7174735B2 (ja) | （ｓ）－３－（４－（（４－（モルホリノメチル）ベンジル）オキシ）－１－オキソイソインドリン－２－イル）ピペリジン－２，６－ジオンの塩及び固体形態、並びにそれらを含有する組成物及び使用方法 | |
| EP3468972B1 (en) | Compounds and compositions for inhibiting the activity of shp2 | |
| EP3310771B1 (en) | Compounds and compositions for inhibiting the activity of shp2 | |
| AU2018358157B2 (en) | Modulators of the integrated stress pathway | |
| EP3094627B1 (en) | 1-pyridazin-/triazin-3-yl-piper(-azine)/idine/pyrolidine derivatives and and compositions thereof for inhibiting the activity of shp2 | |
| EP3310774B1 (en) | Compounds and compositions for inhibiting the activity of shp2 | |
| EP3724178B1 (en) | 1-(piperidinocarbonylmethyl)-2-oxopiperazine derivatives for treating cancer | |
| CN105407889B (zh) | 针对Rb阳性异常细胞增殖的HSPC节制性治疗 | |
| JP2017515802A5 (https=) | ||
| JP2022141811A5 (https=) | ||
| JP2016539138A5 (https=) | ||
| JP7778745B2 (ja) | Ｒｈｏ関連コイルドコイル含有プロテインキナーゼの阻害剤 | |
| CA2943022C (en) | Benzo[g]pyrido[2,1-b] quinazoline carboxamide compounds which inhibit rna polymerase, compositions including such compounds, and their use | |
| KR20210088584A (ko) | 소분자 cd-47 저해제와 다른 항암제의 조합물 | |
| JP2009513562A5 (https=) | ||
| CA3056308A1 (en) | Pharmaceutical compounds | |
| CN110402141A (zh) | Axl抑制剂和EGFR酪氨酸激酶抑制剂的联合疗法 | |
| JP2023505907A (ja) | Ａｈｒインヒビターとｐｄ１インヒビター抗体との組合せおよび癌の治療におけるその使用 | |
| JPWO2020257429A5 (https=) | ||
| JP2020528418A (ja) | ＢＥＴ阻害剤及びＢｃｌ−２阻害剤を用いた併用療法 |